9,070 Shares in Merit Medical Systems, Inc. (NASDAQ:MMSI) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 9,070 shares of the medical instruments supplier’s stock, valued at approximately $877,000.

Other hedge funds have also recently bought and sold shares of the company. Barclays PLC lifted its stake in Merit Medical Systems by 305.4% during the 3rd quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock worth $11,142,000 after acquiring an additional 84,923 shares in the last quarter. EULAV Asset Management lifted its stake in Merit Medical Systems by 400.0% during the 4th quarter. EULAV Asset Management now owns 115,000 shares of the medical instruments supplier’s stock worth $11,123,000 after acquiring an additional 92,000 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Merit Medical Systems by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 221,690 shares of the medical instruments supplier’s stock worth $21,910,000 after acquiring an additional 6,837 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Merit Medical Systems by 85.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock worth $56,921,000 after acquiring an additional 265,648 shares in the last quarter. Finally, AMI Asset Management Corp raised its position in Merit Medical Systems by 28.7% in the 4th quarter. AMI Asset Management Corp now owns 33,041 shares of the medical instruments supplier’s stock valued at $3,196,000 after purchasing an additional 7,367 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Insider Buying and Selling

In related news, CFO Raul Jr. Parra sold 5,361 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $103.58, for a total transaction of $555,292.38. Following the transaction, the chief financial officer now owns 24,201 shares in the company, valued at $2,506,739.58. This trade represents a 18.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Fred P. Lampropoulos sold 31,320 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $103.86, for a total value of $3,252,895.20. Following the transaction, the chief executive officer now owns 1,086,028 shares in the company, valued at $112,794,868.08. This represents a 2.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,132 shares of company stock worth $11,139,521 in the last quarter. 3.70% of the stock is owned by insiders.

Merit Medical Systems Trading Up 0.4 %

MMSI opened at $101.68 on Friday. The business’s 50-day simple moving average is $103.93 and its 200-day simple moving average is $100.78. The company has a market cap of $5.98 billion, a P/E ratio of 49.84, a PEG ratio of 2.34 and a beta of 0.91. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. Merit Medical Systems, Inc. has a one year low of $70.70 and a one year high of $111.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wells Fargo & Company reduced their price target on Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $116.00 price target (up previously from $114.00) on shares of Merit Medical Systems in a research report on Wednesday, January 29th. Raymond James increased their price target on Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday, December 31st. Canaccord Genuity Group reduced their price target on Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reduced their price target on Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.78.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.